Fibroblast-activation protein inhibitors based positron emission tomography (PET) for assessing lung disease: A systematic review with meta-analysis
Our results show that FAPI PET/CT has an excellent diagnostic performance for lung tumours and non-tumour lesions.<b>Points for clinical research</b>: Currently CT is unable to accurately determine the activity of lung diseases such as IPF and hence may lead to delays in the diagnosis and treatment of some lung diseases. We aimed to find evidence-based medical evidence suitable for FAPI PET in lung diseases, especially non-oncological diseases, by performing a meta-analysis of FAPI PET in assessing lung diseases.
Authors
- Qin Zhao (ORCID: https://orcid.org/0000-0002-3519-9190)
- Yu Zhang (ORCID: https://orcid.org/0000-0003-3474-422X)
- Yiren Wang
- Mi Zhou (ORCID: https://orcid.org/0000-0001-8469-5361)
- Qiang Ren (ORCID: https://orcid.org/0000-0002-7188-5999)
- Fuyuan Ran
- Haoshu Zhong
- Delong Huang
- Jun Deng
- Junhao Wu
Institutions
- Fudan University (CN)
- Southwest Medical University (CN)
- Affiliated Hospital of Southwest Medical University (CN)
Publication Details
- Journal
- Pulmonology
- Published
- 2026-03-11
- DOI
- https://doi.org/10.1080/25310429.2026.2638024
- Primary Topic
- Peptidase Inhibition and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 0.00